Bionomics (ASX:BNO) has announced it will proceed with evaluating its lead clinical compound, BNC210, for the treatment of acute treatment of Social Anxiety Disorder while progressing toward the start of its planned Phase 2b trial in Post-Traumatic Stress Disorder. …
Bionomics expands study of BNC210 to include social anxiety disorder
May 11, 2021 Australian Biotech
Latest Video
New Stories
-
If the minister is too embarrassed to respond, it might be the best of bad responses
September 19, 2025 - - Latest News -
Mark Butler acknowledges his concerns over potential impact of US pharmaceutical pricing reforms
September 19, 2025 - - Latest News -
CSL appoints new global head of search to accelerate innovation through strategic partnerships
September 18, 2025 - - Latest News -
Pharmacy Guild of Australia acquires Member Benefits Australia
September 18, 2025 - - Latest News -
Sanofi promotes a national dialogue on health literacy and trust
September 18, 2025 - - Latest News -
Island Pharmaceuticals reports breakthrough survival data for galidesivir in Marburg and Ebola studies
September 17, 2025 - - Australian Biotech -
Australian Dementia Network Registry wants access to 'turning point' therapies
September 17, 2025 - - Latest News